Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Ganglion Sphenopalatine Block Versus Placebo on Persistent Headache Following COVID-19 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Moderate to severe headache (NRS \>= 3) with self reported duration of minimum 6 hours during the past week as well as moderate to severe headache (NRS \>= 3) on the day of intervention.~* Onset of headache during or maximum 4 weeks after PCR-verified COVID-19 infection.~* Headache must have persisted for at least 4 weeks following COVID-19 diagnosis.~Exclusion Criteria:~* Patients who cannot cooperate to the study~* Patients who does not understand or speak Danish~* Allergy to the drugs used in the study~* Has taken opioids within 12 hours prior to intervention~* History of migraine or persistent headache before COVID-19 infection.~* Active COVID-19 infection (defined by the Danish Goverment regulations, i.e. 48 hours after last symptoms (omitting long term effects) or 7 days after positive COVID-19 test if no symptoms.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ropivacaine-Lidocaine (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- Sham-block with Placebo (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).